We are analyzing https://link.springer.com/article/10.1007/bf00686231.

Title:
Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats | Cancer Chemotherapy and Pharmacology
Description:
The effects of fructose-1,6-diphosphate, an intermediate metabolite of glycolysis, on acute and chronic cardiotoxicity of doxorubicin were investigated in rats. In the acute study, urethane-anaesthetized Wistar female rats treated with 10 mg/kg i.v. doxorubicin developed a widening of the SαT segment, an impairment of +dP/dtmax, and tachycardia. Pretreatment with 375 and 750 mg/kg i.p. fructose-1,6-diphosphate prevented the SαT segment from widening, whereas only 750 mg/kg i.p. significantly attenuated the heart rate increase. Chronic cardiomyopathy was induced over a 6-week period by wekly doses of 3 mg/kg i. v. doxorubicin, being characterized in vivo by the progressive enlargement of the SαT segment and the occurrence of histological alterations and in vitro by a marked impairment of the inotropic response elicited by adrenaline in isolated hearts from treated rats. Concurrent treatment with 150 and 300 mg/kg i. p. fructose-1,6-diphosphate thrice a week for 6 weeks did not lessen the chronic heart damage, whereas 600 mg/kg given i. p. significantly reduced the widening of the SαT segment and the severity of histological damage in vivo, as well as significantly improving the contractile responses of hearts in vitro. These findings suggest that the administration of fructose-1,6-diphosphate plays a protective role in the acute and chronic cardiotoxicity of doxorubicin in the rat.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, doxorubicin, cardiotoxicity, heart, article, pharmacol, effects, fructosediphosphate, acute, rat, rats, cancer, bernardini, adriamycin, cardiac, chronic, danesi, mgkg, access, res, privacy, cookies, content, del, tacca, sαt, segment, information, publish, research, search, protective, isolated, treatment, effect, metabolism, cell, chem, anthracycline, histamine, data, log, journal, pharmacology, marchetti, widening, significantly, induced, vivo,

Topics {✒️}

heart rate increase month download article/chapter anti-oxidative stress activities adriamycin-induced histamine release anti-cancer drug adriamycin inotropic response elicited article cancer chemotherapy concurrent treatment privacy choices/manage cookies national research council full article pdf subchronic doxorubicin treatment target project “oncologia” heart cell cultures cardiac histamine release drug-induced cardiomyopathy teniposide-induced cardiotoxicity doxorubicin-induced cardiotoxicity european economic area contractile responses hippocratea africana root related subjects subacute anthracycline cardiotoxicity na+/ca2+ exchange oxygen radical formation adenine nucleotide metabolism van echteld cja phorbol-esterstimulated chemiluminescence chronic heart damage del tacca adriamycin-induced cardiotoxicity isolated rat heart conditions privacy policy check access instant access patients receiving doxorubicin 4′-o-tetrahydropyranyl-doxorubicin acute myocardial ischemia chronic cardiotoxicity produced simple experimental index bullfrog atrial muscle irreversible hemorrhagic shock isolated membrane fractions altered membrane functions chronic doxorubicin cardiotoxicity accepting optional cookies reliable electrocardiogram parameter spontaneously hypertensive rats tumor response journal finder publish

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats
         description:The effects of fructose-1,6-diphosphate, an intermediate metabolite of glycolysis, on acute and chronic cardiotoxicity of doxorubicin were investigated in rats. In the acute study, urethane-anaesthetized Wistar female rats treated with 10 mg/kg i.v. doxorubicin developed a widening of the SαT segment, an impairment of +dP/dtmax, and tachycardia. Pretreatment with 375 and 750 mg/kg i.p. fructose-1,6-diphosphate prevented the SαT segment from widening, whereas only 750 mg/kg i.p. significantly attenuated the heart rate increase. Chronic cardiomyopathy was induced over a 6-week period by wekly doses of 3 mg/kg i. v. doxorubicin, being characterized in vivo by the progressive enlargement of the SαT segment and the occurrence of histological alterations and in vitro by a marked impairment of the inotropic response elicited by adrenaline in isolated hearts from treated rats. Concurrent treatment with 150 and 300 mg/kg i. p. fructose-1,6-diphosphate thrice a week for 6 weeks did not lessen the chronic heart damage, whereas 600 mg/kg given i. p. significantly reduced the widening of the SαT segment and the severity of histological damage in vivo, as well as significantly improving the contractile responses of hearts in vitro. These findings suggest that the administration of fructose-1,6-diphosphate plays a protective role in the acute and chronic cardiotoxicity of doxorubicin in the rat.
         datePublished:
         dateModified:
         pageStart:326
         pageEnd:332
         sameAs:https://doi.org/10.1007/BF00686231
         keywords:
            Doxorubicin
            Diphosphate
            Contractile Response
            Heart Rate Increase
            Concurrent Treatment
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:25
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Romano Danesi
               affiliation:
                     name:Institute of Medical Pharmacology
                     address:
                        name:Institute of Medical Pharmacology, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nunzia Bernardini
               affiliation:
                     name:Institute of Medical Pharmacology
                     address:
                        name:Institute of Medical Pharmacology, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Antonio Marchetti
               affiliation:
                     name:Institute of Pathological Anatomy and Histology
                     address:
                        name:Institute of Pathological Anatomy and Histology, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mariacarla Bernardini
               affiliation:
                     name:Institute of Medical Pharmacology
                     address:
                        name:Institute of Medical Pharmacology, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mario Del Tacca
               affiliation:
                     name:Institute of Medical Pharmacology
                     address:
                        name:Institute of Medical Pharmacology, Pisa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats
      description:The effects of fructose-1,6-diphosphate, an intermediate metabolite of glycolysis, on acute and chronic cardiotoxicity of doxorubicin were investigated in rats. In the acute study, urethane-anaesthetized Wistar female rats treated with 10 mg/kg i.v. doxorubicin developed a widening of the SαT segment, an impairment of +dP/dtmax, and tachycardia. Pretreatment with 375 and 750 mg/kg i.p. fructose-1,6-diphosphate prevented the SαT segment from widening, whereas only 750 mg/kg i.p. significantly attenuated the heart rate increase. Chronic cardiomyopathy was induced over a 6-week period by wekly doses of 3 mg/kg i. v. doxorubicin, being characterized in vivo by the progressive enlargement of the SαT segment and the occurrence of histological alterations and in vitro by a marked impairment of the inotropic response elicited by adrenaline in isolated hearts from treated rats. Concurrent treatment with 150 and 300 mg/kg i. p. fructose-1,6-diphosphate thrice a week for 6 weeks did not lessen the chronic heart damage, whereas 600 mg/kg given i. p. significantly reduced the widening of the SαT segment and the severity of histological damage in vivo, as well as significantly improving the contractile responses of hearts in vitro. These findings suggest that the administration of fructose-1,6-diphosphate plays a protective role in the acute and chronic cardiotoxicity of doxorubicin in the rat.
      datePublished:
      dateModified:
      pageStart:326
      pageEnd:332
      sameAs:https://doi.org/10.1007/BF00686231
      keywords:
         Doxorubicin
         Diphosphate
         Contractile Response
         Heart Rate Increase
         Concurrent Treatment
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:25
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Romano Danesi
            affiliation:
                  name:Institute of Medical Pharmacology
                  address:
                     name:Institute of Medical Pharmacology, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nunzia Bernardini
            affiliation:
                  name:Institute of Medical Pharmacology
                  address:
                     name:Institute of Medical Pharmacology, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Antonio Marchetti
            affiliation:
                  name:Institute of Pathological Anatomy and Histology
                  address:
                     name:Institute of Pathological Anatomy and Histology, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mariacarla Bernardini
            affiliation:
                  name:Institute of Medical Pharmacology
                  address:
                     name:Institute of Medical Pharmacology, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mario Del Tacca
            affiliation:
                  name:Institute of Medical Pharmacology
                  address:
                     name:Institute of Medical Pharmacology, Pisa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:25
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institute of Medical Pharmacology
      address:
         name:Institute of Medical Pharmacology, Pisa, Italy
         type:PostalAddress
      name:Institute of Medical Pharmacology
      address:
         name:Institute of Medical Pharmacology, Pisa, Italy
         type:PostalAddress
      name:Institute of Pathological Anatomy and Histology
      address:
         name:Institute of Pathological Anatomy and Histology, Pisa, Italy
         type:PostalAddress
      name:Institute of Medical Pharmacology
      address:
         name:Institute of Medical Pharmacology, Pisa, Italy
         type:PostalAddress
      name:Institute of Medical Pharmacology
      address:
         name:Institute of Medical Pharmacology, Pisa, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Romano Danesi
      affiliation:
            name:Institute of Medical Pharmacology
            address:
               name:Institute of Medical Pharmacology, Pisa, Italy
               type:PostalAddress
            type:Organization
      name:Nunzia Bernardini
      affiliation:
            name:Institute of Medical Pharmacology
            address:
               name:Institute of Medical Pharmacology, Pisa, Italy
               type:PostalAddress
            type:Organization
      name:Antonio Marchetti
      affiliation:
            name:Institute of Pathological Anatomy and Histology
            address:
               name:Institute of Pathological Anatomy and Histology, Pisa, Italy
               type:PostalAddress
            type:Organization
      name:Mariacarla Bernardini
      affiliation:
            name:Institute of Medical Pharmacology
            address:
               name:Institute of Medical Pharmacology, Pisa, Italy
               type:PostalAddress
            type:Organization
      name:Mario Del Tacca
      affiliation:
            name:Institute of Medical Pharmacology
            address:
               name:Institute of Medical Pharmacology, Pisa, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Institute of Medical Pharmacology, Pisa, Italy
      name:Institute of Medical Pharmacology, Pisa, Italy
      name:Institute of Pathological Anatomy and Histology, Pisa, Italy
      name:Institute of Medical Pharmacology, Pisa, Italy
      name:Institute of Medical Pharmacology, Pisa, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(68)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.15s.

LINK . SPRINGER . COM {}